Formal Name: ((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((R)-2-((S)-2-((R)-2-((S)-2-((R)-2-(2-((R)-2-((S)-2-((R)-2-acetamido-5-guanidinopentanamido)-5-guanidinopentanamido)-5-guanidinopentanamido)acetamido)-5-guanidinopentanamido)-6-aminohexanamido)-6-aminohexanamido)-5-guanidinopentanamido)-5-guanidinopentanamido)-3-hydroxypropanamido)-3-(1H-imidazol-5-yl)propanamido)-3-(1H-indol-3-yl)propanamido)-3,3-dimethylbutanamido)-2-cyclohexylacetyl)-L-aspartyl-L-isoleucine, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C96H165N39O21 • XCF3COOH
Formula Weight: 2201,6
Shelf life (days): 1460
Notes: KSL-128114 is a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM).{66501} It reduces the percent viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. KSL-128114 (50 µM) increases animal survival time in a patient-derived xenograft (PDX) mouse model of GBM using patient-derived GBM cells cultured with KSL-128114 prior to intracranial implantation.